The post-traumatic stress disorder (PTSD) market is expected to grow from $1.2 billion in 2024 to $5.5 billion by 2034 across the seven major markets (7MM*) at a compound annual growth rate (CAGR) of 16.1%, primarily driven by the entry of eight novel late-stage pipeline products that are all anticipated to be significantly more expensive than the widely used generic drugs currently dominating the market and an increasing awareness and reduced stigma surrounding PTSD in the general population, leading to higher rates of healthcare presentation and increased diagnosis and treatment rates, according to GlobalData, a leading data and analytics company.
GlobalData’s latest report, “Post-Traumatic Stress Disorder: Opportunity Assessment and Forecast”, reveals that a major focus of research and development (R&D) in the PTSD therapeutic space is the development of new therapeutic options with improved efficacy, with a significant area of research going into psychedelic therapeutics.
Philippa Salter, Managing Neurology Analyst at GlobalData, comments: “Key opinion leaders (KOLs) interviewed by GlobalData consistently highlighted midomafetamine hydrochloride (MDMA) as the most promising psychedelic therapeutic for PTSD, with Lykos Therapeutics’ MDMA-assisted psychotherapy expected to achieve blockbuster status by the end of the forecast period.
“Despite a challenging path towards market, having been initially rejected by the FDA in August 2024 and KOLs noting some concerns surrounding trial design and company practice, as the first psychedelic to reach the market for PTSD, GlobalData forecasts Lykos’ drug will generate $1.1 billion in sales across the 7MM by 2034.”
Other psychedelic therapeutics in the late-stage pipeline are Compass Pathways’ psilocybin and Seelos Therapeutics’ ketamine. In addition to the three psychedelic therapeutics, there are also five non-psychedelic pipeline products in the late-stage PTSD pipeline that GlobalData expects to launch during the forecast period (2024–34).
Salter continues: “Many of these products have safety profiles favorable to the current treatment options, helping to meet another key unmet need in the PTSD market as the problem of side effects with existing treatments leads to low patient compliance rates.”
GlobalData expects that the five non-psychedelic pipeline products will generate $2.3 billion in sales in the 7MM by 2034.
Salter concludes: “While the PTSD market is poised to grow significantly as it shifts away from the currently used generic treatment options, it remains to be seen if novel challenges will arise, such as access to the more expensive pipeline products.”
* 7MM = US, France, Germany, Italy, Spain, UK, and Australia
